Therapeutic efficacy of a novel immunotherapeutic formulation, combining a multi-epitope chimeric protein and Amphotericin B, in murine L. infantum infection
Parasitology International · 2026
DOI: 10.1016/j.parint.2026.103256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Parasitology International, 2026. Verfasst von Júlia Kelly Campos und 16 weiteren Autor:innen. Beteiligte Einrichtung: Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo H…. Hauptthemen laut MEDLINE: Amphotericin B, Leishmaniasis, Visceral, Leishmania infantum, Immunotherapy.
Abstract (Originalsprache)
Leishmaniasis is a vector-borne parasitic disease caused by Leishmania protozoa. First-line treatment with pentavalent antimonials faces increasing resistance and significant toxicity. Amphotericin B is an effective second-line alternative but is also toxic and complex to administer, with a safer but expensive liposomal formulation. This study evaluated an immunotherapeutic approach using a chimeric protein composed of multiple T-cell epitopes from Leishmania (L.) infantum, combined with the adjuvant Monophosphoryl Lipid A (MPLA), in a murine model of VL. Our findings demonstrate that the combined rChi+MPLA/Amp-B therapy significantly outperformed monotherapies, inducing a robust TH1-polarized immune response. Splenocytes from this group exhibited markedly higher levels of TNF in both CD4+ (SC/CC = 1.64) and CD8+ T cells (SC/CC = 1.93) compared to Saline, MPLA, and rChi controls (p < 0.05). Furthermore, the combination therapy achieved a significantly higher IFN-γ/IL-10 ratio in CD4+ cells (Ratio = 2.03) compared to Saline, MPLA, and rChi groups (p < 0.05), indicating a shift away from the immunosuppressive environment characterized by high IL-10 levels in untreated Saline controls (SC/CC = 1.58). This protective environment was further corroborated by a marked elevation in nitric oxide (NO) levels in the rChi+MPLA/Amp-B group compared to all other experimental groups (p < 0.05). This potent immune activation correlated with a drastic reduction in parasite load. The rChi+MPLA/Amp-B group achieved statistically significant reductions (p < 0.05) of 98.4% in the lymph nodes, 99.1% in the spleen, and 97.8% in the liver compared to the Saline group. These reductions were also significantly superior (p < 0.05) to those observed in animals treated with Amp-B alone (82.1%, 89.3%, and 79.4%) or rChi+MPLA alone (75.2%, 68.5%, and 72.1%) in the lymph nodes, spleen, and liver, respectively. These results highlight the potential of the rChi+MPLA/Amp-B formulation as a highly effective immunotherapeutic strategy to enhance conventional chemotherapy and improve the clinical management of VL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
- Laboratório de Química Orgânica Sintética, Instituto de Química, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil.
- Laboratório de Pesquisas Clínicas, Programa de Pós-graduação em Ciências Farmacêuticas/CiPharma, Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, Brazil.
- Departamento de Patologia Clínica, COLTEC, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
- Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, Criciúma, Santa Catarina, Brazil; Programa de Pós-graduação em Microbiologia, Parasitologia e Patologia, Universidade Federal do P…
- Programa de Pós-graduação em Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Zitieren
APA
Campos, J. K., Costa, S. S., Ribeiro, N. R., Lage, D. P., Dos Reis Cruz, L., Moreira, G. J. L., Souza, T. M., Moura E Souza, A. C., de Souza Dutra, G. C., de Ávila, R. A. M., Carvalho, A. M. R. S., Eleutério, N. M., Fernandes, A. P. S. M., Coelho, E. A. F., Roatt, B. M., Menezes-Souza, D., & Duarte, M. C. (2026). Therapeutic efficacy of a novel immunotherapeutic formulation, combining a multi-epitope chimeric protein and Amphotericin B, in murine L. infantum infection. Parasitology International. https://doi.org/10.1016/j.parint.2026.103256
Vancouver
Campos JK, Costa SS, Ribeiro NR, Lage DP, Dos Reis Cruz L, Moreira GJL, et al. Therapeutic efficacy of a novel immunotherapeutic formulation, combining a multi-epitope chimeric protein and Amphotericin B, in murine L. infantum infection. Parasitology International. 2026. doi:10.1016/j.parint.2026.103256
BibTeX
@article{Campos2026,
author = {Campos, Júlia Kelly and Costa, Scarleth Silva and Ribeiro, Naianda Rezende and Lage, Daniela Pagliara and Dos Reis Cruz, Luiza and Moreira, Gabriel José Lucas and Souza, Thiago Miranda and Moura E Souza, Ana Clara and de Souza Dutra, Gabrielle Caroline and de Ávila, Ricardo Andrez Machado and Carvalho, Ana Maria Ravena Severino and Eleutério, Níbia Mariana and Fernandes, Ana Paula Salles Moura and Coelho, Eduardo Antonio Ferraz and Roatt, Bruno Mendes and Menezes-Souza, Daniel and Duarte, Mariana Costa},
title = {Therapeutic efficacy of a novel immunotherapeutic formulation, combining a multi-epitope chimeric protein and Amphotericin B, in murine L. infantum infection},
journal = {Parasitology International},
year = {2026},
doi = {10.1016/j.parint.2026.103256}
}
EUVIMED